Prognostic value of unrelated atypical serum immunofixation patterns during Multiple Myeloma therapy

5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Autologous stem cell transplantation (ASCT) is the gold standard therapy for suitable multiple myeloma (MM) patients after induction with high dose therapy. To date, the evidence of a reliable marker of prognosis in these cases remains scarce. Our aim was to evaluate appearance of unrelated atypical serum immunofixation patterns (ASIPs) as a marker of prognosis in MM patients submitted to ASCT. We retrospectively analysed data from 65 patients. Interestingly, we observed that presence of ASIPs was associated with longer progression-free survival and longer overall survival. Our results suggested that presence of ASIPs could be a novel marker of good prognosis in MM patients submitted to ASCT. © 2012 Guimaraes et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Guimarães, C., Bergantim, R., Ramalho, R., Couto, N., Guimarães, J. T., & Trigo, F. (2012). Prognostic value of unrelated atypical serum immunofixation patterns during Multiple Myeloma therapy. Journal of Hematology and Oncology, 5. https://doi.org/10.1186/1756-8722-5-33

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free